Biopharma's no-holds-barred fight to find a COVID-19 vaccine: The full list

A pipette labeled Covid-19
Many players are using vaccine platforms they’ve previously deployed against other epidemics, including Johnson & Johnson and Sanofi Pasteur as well as universities like Imperial College London. (Getty/Bill Oxford)

UPDATED: Friday, April 17 at 11 a.m. ET

Since Moderna kicked off a human trial of its mRNA vaccine, the company has secured up to $483 million from the Biomedical Advanced Research and Development Authority (BARDA) to bankroll late-stage trials for the vaccine as well as step up its manufacturing. If its phase 1 study goes to plan, the company expects to start a phase 2 trial in the second quarter, with phase 3 to follow as early as this fall.

BioNTech and CureVac, two German biotechs also developing mRNA vaccines, told regulators earlier this month that some clinical trial hurdles should be removed if governments want to introduce vaccines as quickly as possible. And Sanofi jumped on the mRNA bandwagon, too, expanding its infectious disease pact with Translate Bio to include COVID-19. It joins its Big Pharma peer Pfizer, which is collaborating with BioNTech.

Biopharma companies continued to strike partnerships with each other as well as with public agencies. Johnson & Johnson and BARDA are committing as much as $1 billion to develop a vaccine, while GlaxoSmithKline allied with Vir Biotechnology on COVID-19 research. Their first focus will be a pair of therapeutic antibodies, but the duo will work on vaccines as well.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

UPDATED: Friday, March 20 at 10:23 a.m. ET

The hunt is well underway for medicines to combat COVID-19, but it will be longer for vaccines, which protect the body against the disease, than it will for drug treatments, which fight infection once a person has fallen ill.

In March, Moderna became the first biopharma company to test a COVID-19 vaccine in humans, with partners BioNTech and Pfizer aiming to follow suit within weeks. But even though Moderna’s mRNA vaccine made it to phase 1 in record time, experts warn that the 12- to 18-month development time frame suggested by government officials is "overly optimistic." Expect drug treatments to score approval first and act as a “bridge” while the world waits for a vaccine.

Big Pharma companies, small startups, universities and research institutes are working on different types of vaccines, from those with inactivated or weakened versions of the virus to DNA and RNA versions. Behind Moderna, CanSino Biologics secured approval to test its adenovirus-based viral vector vaccine in China, and Johnson & Johnson plans to start human trials of a non-replicating viral vector in November.

RELATED: Biopharma's leading treatment hopes against COVID-19

Many players are using vaccine platforms they’ve previously deployed against other epidemics—J&J has worked on vaccines for Ebola, HIV and respiratory syncytial virus using its platform, while Sanofi Pasteur has used its protein subunit technology against influenza and SARS.

RELATED: Moderna wins bragging rights as it kick-starts first experimental coronavirus clinical trial

Here’s a guide to the vaccines in development against COVID-19, compiled by the World Health Organization. Six other institutions, such as the University of Pittsburgh and Tulane University, are also researching potential vaccines, but at earlier stages.

 

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.